By BRETT NUCKLES ThisWeek Community News Wednesday September 26, 2012 8:38 AM Powell residents can dispose of prescription drugs, old electronics and sensitive personal documents all in one trip this weekend. From 10 a.m. to 2 p.m. Saturday, Sept. 29, the Powell Police Department will host an annual take-back day for expired, unused and unwanted prescription drugs at the Powell Police Department, 47 Hall St. On the same day, the city will host its second annual electronic recycling drop-off day, accepting old and unwanted electronics from 9 a.m. to 1 p.m. in the parking lot at the Village Green Municipal Building, connected to the police station. Also Sept. 29, the Greater Area Powell Chamber of Commerce will hold an annual document shredding day for sensitive personal and financial paperwork from 9 a.m. to 1 p.m. at the chamber's offices, just up the road at 50 N. Liberty St. The drug take-back service is free and anonymous with no questions asked, said police clerk Patti Mills. Residents can enter the police department and drop off unwanted pills in a box in the lobby. The drugs must be removed from pill bottles or other containers before being deposited, and no liquids, sharp … Continue reading →

It's likely going to take a cocktail of drugs to fight hepatitis C, but you need only one from each class of drugs. Attacking the virus from multiple angles is the way to go. So it's a good thing that Vertex Pharmaceuticals (Nasdaq: VRTX) licensed two hepatitis C drugs from Alios BioPharma, because only one of them made it past the critical phase 1 clinical trial. Vertex is dropping development of ALS-2158 after it failed to produce enough antiviral activity to justify taking it further into the clinic. The other drug that Vertex got in the deal, ALS-2200, which it's calling VX-135, looks much better. We already saw solid data from a phase 1 trial by itself, and yesterday Vertex followed that up with data from patients that took ALS-2200 with ribavirin, a generic antiviral drug. The median reduction in virus levels for the combination therapy wasn't quite as good as the group that got ALS-2200 alone, but the percent of patients reaching undetectable levels was slightly higher. Of course, were talking about only eight patients. It's going to take a phase 2 and eventually a phase 3 trial to confirm that ALS-2200 works. Vertex plans to evaluate ALS-2200 in … Continue reading →

ALBANY, New York, September 26, 2012 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Global Diabetes Devices Market and Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share and Forecast, 2011-2018," the global diabetes devices and drugs market was worth USD 50.8 billion in 2011 and is expected to reach USD 98.4 billion in 2018, growing at a CAGR of 9.9% from 2011 to 2018. In the overall global market, North America accounted for the highest share worth USD 19.9 billion in 2011 followed by Europe. However, with the continuous population and economic growth of the Asia-Pacific region, especially India and China, it is expected to witness the highest growth rate in the next six years. Browse the full report athttp://www.transparencymarketresearch.com/diabetes-devices-market.html Today, diabetes is one of the major areas of concern worldwide. The rising number of patients is due to the ever increasing population around the globe mainly in the Asia Pacific region. Currently, over 370 million people suffer from diabetes across the globe, which is expected to exceed 550 million by 2030. As of now, the age bracket of 40-59 years is the most affected diabetes population followed by the age group … Continue reading →